Early treatment-related neutropenia predicts response to palbociclib.

ABSTRACT:

Background

Palbociclib is highly active in oestrogen-receptor positive (ER+) metastatic breast cancer, but neutropenia is dose limiting. The goal of this study was to determine whether early neutropenia is associated with disease response to single-agent palbociclib.

Methods

Blood count and disease-response data were analysed from two Phase 2 clinical trials at different institutions using single-agent palbociclib: advanced solid tumours positive for retinoblastoma protein and advanced liposarcoma. The primary endpoint was PFS. The primary exposure variable was the nadir absolute neutrophil count (ANC) during the first two cycles of treatment.

Results

One hundred and ninety-six patients (61 breast, 135 non-breast) were evaluated between the two trials. Development of

SUBMITTER: McAndrew NP 

PROVIDER: S-EPMC7492243 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature